• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Bicycle Therapeutics plc

    5/15/25 4:34:33 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCYC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    BICYCLE THERAPEUTICS PLC

    (Name of Issuer)


    Ordinary Shares, nominal value 0.01 GBP per share

    (Title of Class of Securities)


    088786108

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    088786108


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,739,318.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,739,318.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,739,318.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Represented by 3,739,318 ADSs (as defined in Item 2(a)).


    SCHEDULE 13G

    CUSIP No.
    088786108


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,739,318.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,739,318.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,739,318.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Represented by 3,739,318 ADSs.


    SCHEDULE 13G

    CUSIP No.
    088786108


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,739,318.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,739,318.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,739,318.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Represented by 3,739,318 ADSs.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BICYCLE THERAPEUTICS PLC
    (b)Address of issuer's principal executive offices:

    Blocks A & B, Portway Building Granta Park, Great Abington Cambridge United Kingdom CB21 6GS
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the ordinary shares, nominal value 0.01 GBP per share ("Ordinary Shares"), of Bicycle Therapeutics plc (the "Issuer") held, in the form of American Depositary Shares ("ADSs"), by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to Ordinary Shares held, in the form of ADSs, by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to Ordinary Shares beneficially owned, in the form of ADSs, by Point72 Asset Management and Point72 Capital Advisors Inc. Cubist Systematic Strategies, LLC, an advisor under common control with Point72 Asset Management, acts as a sub-advisor with respect to a portion of the Ordinary Shares reported herein. There is no CUSIP number assigned to the Ordinary Shares. The CUSIP Number 088786108 has been assigned to the ADSs of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol "BCYC." Each ADS represents 1 Ordinary Share.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Ordinary Shares, nominal value 0.01 GBP per share
    (e)CUSIP No.:

    088786108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2025. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Ordinary Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities and Exchange Act of 1934, the beneficial owner of the Ordinary Shares reported herein.
    (b)Percent of class:

    7.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2025.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2025.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2025.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2025.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Ordinary Shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:05/15/2025
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:05/15/2025
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:05/15/2025
    Get the next $BCYC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCYC

    DatePrice TargetRatingAnalyst
    11/8/2024$25.00Equal-Weight
    Stephens
    9/6/2024$35.00Outperform
    RBC Capital Mkts
    8/7/2024$33.00 → $28.00Buy → Neutral
    B. Riley Securities
    9/11/2023Neutral → Buy
    B. Riley Securities
    8/31/2022Outperform
    Cowen
    7/28/2022$30.00Overweight
    Barclays
    7/6/2022$60.00Buy
    Canaccord Genuity
    4/13/2022$62.00 → $33.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $BCYC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Young Alethia sold $1,724 worth of Ordinary Shares (215 units at $8.02), decreasing direct ownership by 0.47% to 45,390 units (SEC Form 4)

      4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

      4/4/25 5:35:13 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF TECHNOLOGY OFFICER Skynner Michael sold $14,293 worth of Ordinary Shares (1,852 units at $7.72), decreasing direct ownership by 1% to 121,870 units (SEC Form 4)

      4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

      4/4/25 5:35:11 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Lee Kevin sold $43,612 worth of Ordinary Shares (5,669 units at $7.69), decreasing direct ownership by 1% to 486,265 units (SEC Form 4)

      4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

      4/4/25 5:35:09 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on May 1, 2025, the Compensation Committee of the company's Board of Directors granted to 13 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 79,500 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price equal to $8.56 per share, Bicycle Therapeutics' closing trading price on April 30, 2025, and will vest over four years, with 25% of t

      5/5/25 4:05:00 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

      Multiple abstracts accepted for presentation at 2025 ASCO and AACR annual meetings underscore breadth of Bicycle® technology and potential of oncology pipeline Phase 1/2 Duravelo-3 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer open and actively recruiting patients Bolstered business and clinical expertise with appointments to Board of Directors, Clinical Advisory Board and company management team Cash and cash equivalents of $793.0 million as of March 31, 2025, with expected financial runway into 2H 2027 Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide

      5/1/25 7:00:00 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

      Data continue to validate the potential of MT1-MMP as a novel cancer target and further underscore the applicability of Bicycle® Radioconjugates (BRC®) for radiopharmaceutical imaging Data are representative of 12 patients with various solid tumors imaged with an early BRC molecule targeting MT1-MMP Initial human imaging data for second BRC molecule targeting EphA2 expected in 2H 2025 Company-sponsored radiopharmaceutical clinical trials planned for 2026 Bicycle Therapeutics plc (NASDAQ:BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced the presentation of additional hum

      4/29/25 7:00:00 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on Bicycle Therapeutics with a new price target

      Stephens initiated coverage of Bicycle Therapeutics with a rating of Equal-Weight and set a new price target of $25.00

      11/8/24 7:35:57 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Bicycle Therapeutics with a new price target

      RBC Capital Mkts initiated coverage of Bicycle Therapeutics with a rating of Outperform and set a new price target of $35.00

      9/6/24 7:31:26 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Bicycle Therapeutics from Buy to Neutral and set a new price target of $28.00 from $33.00 previously

      8/7/24 6:40:33 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Bicycle Therapeutics plc

      SCHEDULE 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

      5/15/25 4:34:33 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Bicycle Therapeutics plc

      SCHEDULE 13G - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

      5/15/25 3:08:57 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Bicycle Therapeutics plc

      10-Q - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)

      5/1/25 7:10:27 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

      SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

      12/17/24 6:46:27 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

      SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

      11/14/24 5:46:12 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

      SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

      11/14/24 4:32:50 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Financials

    Live finance-specific insights

    See more
    • Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

      Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025 Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated an enhanced response to zelenectide pevedotin Company to advance development strategy leveraging NECTIN4 gene amplification, with Phase 1/2 trials in breast cancer, lung cancer and multi-tumor planned for 2025 Bicycle Therapeutics to host conference call and webcast with management and

      12/12/24 6:30:00 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

      Abstract outlines data showing enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer patients with NECTIN4 gene amplification Company to announce topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer Conference call and webcast scheduled for Friday, Dec. 13, at 7 a.m. CT to review all data Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the

      11/25/24 5:30:00 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

      First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use Additional preclinical data demonstrate biodistribution of BRCs can be optimized to maintain high tumor uptake while significantly reducing kidney levels Company strategy focuses on pursuing novel targets using a range of isotopes to develop radiopharmaceuticals with first-in-class potential Bicycle Therapeutics to host conference call and webcast today at 8 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therap

      10/23/24 7:00:00 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Leadership Updates

    Live Leadership Updates

    See more
    • Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

      Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer; Duravelo-2 dose selection data expected in 2H 2025 Enhanced response to zelenectide pevedotin seen in NECTIN4 gene-amplified late-line breast cancer and non-small cell lung cancer (NSCLC), resulting in U.S. FDA Fast Track designations for triple-negative breast cancer and NSCLC; several Phase 1/2 trials expected to start in 2025 Advancing radiopharmaceuticals pipeline, with additional MT1-MMP human imaging data expected in mid-2025 and first EphA2 human imaging data planned for

      2/25/25 7:00:00 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

      Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the company's clinical oncology programs. "We are delighted to welcome Skip, Markus and Niklas to our Clinical Advisory Board. Each of them has dedicated their careers to advancing the care of patients with cancer through the development of novel therapeutics," said Bicycle Therapeutics CEO Kevin Lee, Ph.D. "Their expertise will provide invaluable guidance

      12/10/24 7:00:00 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

      EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director. Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ:BCYC), Kevin brings two decades of biotech and pharma experience to Macomics. In addition to his seat on Bicycle's board of directors, he is also a non-executive director of Alchemab Therapeutics Ltd. Kevin has led Bicycle Therapeutics since 2015, steering it through its strategic growth including various collaborations and financings including through its listing on NAS

      10/19/23 4:00:00 AM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCYC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $21,230,385 worth of American Depositary Shares (1,485,397 units at $14.29) (SEC Form 4)

      4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

      12/17/24 6:03:39 PM ET
      $BCYC
      Biotechnology: Pharmaceutical Preparations
      Health Care